Univariate and multivariate analyses of prognostic factors
| Prognostic factor . | Patients tested at initial diagnosis . | Patients tested beyond initial diagnosis . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate . | Multivariate . | Univariate . | Multivariate . | |||||
| Median survival, mo . | P . | Hazard ratio . | P . | Median survival, mo . | P . | Hazard ratio . | P . | |
| Age | ||||||||
| Less than 65 years | 57 | .009 | 1.6 | .05 | 46 | .001 | 2.2 | .002 |
| 65 years or more | 29 | 20 | ||||||
| Performance status | ||||||||
| 0 | 57 | < .001 | 2.6 | < .001 | 34 | .008 | — | NS |
| 1 or more | 23 | 21 | ||||||
| Hemoglobin | ||||||||
| 10 g/dL or more | 60 | < .001 | 2.3 | .001 | 54 | < .001 | — | NS |
| Less than 10 g/dL or TD | 26 | 21 | ||||||
| WCC | ||||||||
| 4-30 × 109/L | 52 | .04 | — | NS | 29 | .04 | 1.8 | .03 |
| Less than 4/more than 30 × 109/L | 29 | 16 | ||||||
| Platelet count | ||||||||
| 100 or more × 109/L | 53 | < .001 | 2.3 | .003 | 40 | < .001 | 2.6 | < .001 |
| Less than 100 × 109/L | 16 | 13 | ||||||
| Monocytes | ||||||||
| Less than 1.0 × 109/L | 50 | .05 | — | NS | — | NS | — | NS |
| 1.0 or more × 109/L | 32 | |||||||
| Peripheral blasts | ||||||||
| Less than 2% | 46 | .004 | — | NS | 34 | .05 | 1.9 | .007 |
| 2% or more | 24 | 21 | ||||||
| Diploid or nonunfavorable CG | 48 | .002 | 3.5 | .003 | 29 | < .001 | 2.6 | .004 |
| Unfavorable or very unfavorable CG | 6 | 7 | ||||||
| Prognostic factor . | Patients tested at initial diagnosis . | Patients tested beyond initial diagnosis . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate . | Multivariate . | Univariate . | Multivariate . | |||||
| Median survival, mo . | P . | Hazard ratio . | P . | Median survival, mo . | P . | Hazard ratio . | P . | |
| Age | ||||||||
| Less than 65 years | 57 | .009 | 1.6 | .05 | 46 | .001 | 2.2 | .002 |
| 65 years or more | 29 | 20 | ||||||
| Performance status | ||||||||
| 0 | 57 | < .001 | 2.6 | < .001 | 34 | .008 | — | NS |
| 1 or more | 23 | 21 | ||||||
| Hemoglobin | ||||||||
| 10 g/dL or more | 60 | < .001 | 2.3 | .001 | 54 | < .001 | — | NS |
| Less than 10 g/dL or TD | 26 | 21 | ||||||
| WCC | ||||||||
| 4-30 × 109/L | 52 | .04 | — | NS | 29 | .04 | 1.8 | .03 |
| Less than 4/more than 30 × 109/L | 29 | 16 | ||||||
| Platelet count | ||||||||
| 100 or more × 109/L | 53 | < .001 | 2.3 | .003 | 40 | < .001 | 2.6 | < .001 |
| Less than 100 × 109/L | 16 | 13 | ||||||
| Monocytes | ||||||||
| Less than 1.0 × 109/L | 50 | .05 | — | NS | — | NS | — | NS |
| 1.0 or more × 109/L | 32 | |||||||
| Peripheral blasts | ||||||||
| Less than 2% | 46 | .004 | — | NS | 34 | .05 | 1.9 | .007 |
| 2% or more | 24 | 21 | ||||||
| Diploid or nonunfavorable CG | 48 | .002 | 3.5 | .003 | 29 | < .001 | 2.6 | .004 |
| Unfavorable or very unfavorable CG | 6 | 7 | ||||||
Adverse cytogenetics were independently associated with inferior survival in both patients tested at diagnosis, and those tested beyond initial diagnosis.
TD indicates transfusion dependent; WCC, white cell count; NS, not significant; and CG, cytogenetics.